Shanghai export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
Archive — March 2024
Page 2 of 5 of this archive, newest first.
Germany pharmacy body issues counselling standards for exenatide initiation
The evidence base is thin and the document says so, which is to its credit.
The relabeller trading as Vantris Bio enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
Diminishing returns, quantified
The ceiling in this class is anatomical: the same receptor populations that suppress appetite provoke nausea, and they saturate together.
Who signed this, and what did they undertake by signing it
What the Journal asks when a document arrives unsigned, and what the answers have been.
A supplier suspends shipping to Mexico after 23 consecutive customs detentions
The route did not close because of a rule about peptides.
What a 27% rise in coupling-reagent prices does to a 15 mg vial
Follow the resin, not the catalogue.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
Denmark health authority warns on falsified semaglutide pens
Reported from the analysis, not from a warning notice.
How a correct calculation becomes a wrong dose
Almost every case involves a change — a new vial, a new syringe size, a new supplier — carried forward with an old number.
HbA1c and its lag: what a result three months old is telling you
HbA1c integrates roughly three months of glycaemia with the most recent weeks weighted most heavily. Almost every misreading of it is a misreading of that weighting.
Twelve things a real certificate has, and what their absence means
The header identifies the batch, the table records the tests, and the footer says who is answerable. Two of the three are usually incomplete.
TRIUMPH-3 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Mexico declines to reimburse dulaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
The quiet end of the relabeller trading as Vantris Bio
A proper account of an operation that existed, and of what closing it cost.
What TRIUMPH-3 tells us about maintenance, and what it does not
A survey of the maintenance evidence, which is shorter than the survey of the withdrawal evidence.
What a 33% rise in coupling-reagent prices does to a 20 mg vial
Follow the resin, not the catalogue.
Portugal caps tirzepatide prescribing to 5 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
The consolidator trading as Meridian Freight Partners closes after 7 years
A proper account of an operation that existed, and of what closing it cost.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
Four ways a peptide comes apart
Deamidation, oxidation, aggregation and hydrolysis account for nearly all of what happens to a peptide over time. Each has a characteristic residue, a characteristic…
What STEP 4 and SURMOUNT-4 actually established
The dose-response curve in this class flattens near its top. That has direct consequences for whether the final rung is worth climbing.
Australia health authority warns on falsified tirzepatide pens
Reported from the analysis, not from a warning notice.
Shanghai export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
What the new Saudi Arabia guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
From the floor in Changsha: 11 posters, one theme
Reported from the sessions, and from the two hours afterwards.
What happens when the drug is taken away: three randomised answers
The regain trajectories, arm by arm, with the estimands named.
The dose that got you here and the dose that keeps you here
What the labels permit, what clinicians do, and the size of the gap between them.
What changed at HJ in March, and what the company says prompted it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
A supplier suspends shipping to Saudi Arabia after 19 consecutive customs detentions
The route did not close because of a rule about peptides.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
What the GLP-1 receptor actually does when mazdutide binds it
Selectivity, potency and efficacy are three different measurements. The trade routinely reports none of them.
Oxidation, and the peroxide that came in with the surfactant
The sequence predicts the failure mode. A methionine predicts oxidation; an asparagine followed by a glycine predicts deamidation; a cysteine predicts disulphide scrambling.
South Africa pharmacy body issues counselling standards for dulaglutide initiation
The evidence base is thin and the document says so, which is to its credit.
The 22-day notice: how a compounding wind-down works in Ireland
The document is four pages. Three of them are about dates.
The consolidator trading as Meridian Freight Partners closes after 9 years
A proper account of an operation that existed, and of what closing it cost.
Norway caps liraglutide prescribing to 17 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
The advice is mostly reasonable. The certainty is not earned.
A tour of the source literatures, with an assessment of how far each legitimately reaches.
D-amino acids are invisible to mass spectrometry, and that is the whole problem
What would be needed to catch each of these, and what it would cost.